This article is a correction to:
Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening
Siyu Zhang1
Changxin Huang1*Yongqiang Li1Zhaoyang Li1Ying Zhu2Lili Yang1Haokun Hu1Quan Sun1Mengmeng Liu3
Songqiang Cao4- 1Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
- 2Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
- 3Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Kaifeng, China
- 4Department of Urology, Huaihe Hospital of Henan University, Kaifeng, China
A Corrigendum on
Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening
By Zhang S, Huang C, Li Y, Li Z, Zhu Y, Yang L, Hu H, Sun Q, Liu M and Cao S (2024) Front. Immunol. 15:1473145. doi: 10.3389/fimmu.2024.1473145
In the published article, there was two error in affiliation(s) 2.
1. Instead of “3Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Hangzhou, China”, it should be “3Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Kaifeng, China”.
2. Instead of “4Department of Urology, Huaihe Hospital, Henan University, Kaifeng City, China”, it should be “4Department of Urology, Huaihe Hospital of Henan University, Kaifeng, China”.
In the published article, there was an error in the legend for Figure 5 as published. “The percentages of T, B and NK cells in the mixed cells were identified by flow cytometry in control group shows the experimental group after adding peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 14.63%, 7.81% and 1.40%, respectively” The corrected legend appears below.
Figure 5
Figure 5. The percentages of T, B, and NK cells in the mixed cell population were analyzed by flow cytometry in the control group, which did not include the addition of peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.
“The percentages of T, B, and NK cells in the mixed cell population were analyzed by flow cytometry in the control group, which did not include the addition of peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.”
In the published article, there was an error in the Funding statement. “This work was supported by grants from major science and technology project of Zhejiang Province, China (Project number: 4125C4011724448), the Hangzhou Science and Technology Development Program Project (Project number: 202004A21), Hangzhou Medical and Health Technology Project (Project number: A20220868), Hangzhou Biomedicine and Health Industry Development Support Project (Project number: 2022WJC030), and Henan Province Medical Science and Technology Research Program Project (Project number: LHGI20230440).” The correct Funding statement appears below.
“This work was supported by grants from major science and technology project of Zhejiang Province, China (Project number: 2017C03053), the Hangzhou Science and Technology Development Program Project (Project number: 202004A21), Hangzhou Medical and Health Technology Project (Project number: A20220868), Hangzhou Biomedicine and Health Industry Development Support Project (Project number: 2022WJC030), and Henan Province Medical Science and Technology Research Program Project (Project number: LHGI20230440).”
In the published article, there were three errors.
1. A correction has been made to Abstract, Results, 1. This sentence previously stated:
“3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 14.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.”
The corrected sentence appears below:
“3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 4.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.”
2. A correction has been made to 3.3 The cellular immune effect induced by neoantigen peptides, 3.3.2 Investigating the percentages of T, B and NK cells in the final activated immune cells, 1. This sentence previously stated:
“The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 14.63%, 7.81% and 1.40%, respectively.”
The corrected sentence appears below:
“The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.”
3. A correction has been made to 3 Results, 3.4 Neoantigen peptide ELISpot results, 4. This sentence previously stated:
“Immunogenicity quantification enabled determination of the relationship between a neoantigen’s immune effects and its HLA molecular affinity changes, as depicted in Chart 1.”
The corrected sentence appears below:
“Immunogenicity quantification enabled determination of the relationship between a neoantigen’s immune effects and its HLA molecular affinity changes, as depicted in Supplementary Material.”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tumor immunotherapy, tumor vaccine, neoantigen, MHC molecular affinity, colorectal cancer
Citation: Zhang S, Huang C, Li Y, Li Z, Zhu Y, Yang L, Hu H, Sun Q, Liu M and Cao S (2024) Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening. Front. Immunol. 15:1514836. doi: 10.3389/fimmu.2024.1514836
Received: 21 October 2024; Accepted: 20 November 2024;
Published: 03 December 2024.
Edited by:
Wenxue Ma, University of California, San Diego, United StatesReviewed by:
Rong-Hua Tao, University of Texas MD Anderson Cancer Center, United StatesCopyright © 2024 Zhang, Huang, Li, Li, Zhu, Yang, Hu, Sun, Liu and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Changxin Huang, aGN4NTg4QGhvdG1haWwuY29t